Positive interaction between lapatinib and capecitabine in human breast cancer models: Study of molecular determinants

Fundamental and Clinical Pharmacology

Volumn 26, Issue 4, 2012, Pages 530-537

  Chefrour, Mohamed ^a,b   Milano, Gérard ^a   Formento, Patricia ^a   Giacometti, Sarah ^b   Denden, Amine ^c   Renée, Nicole ^a   Iliadis, Athanassios ^b   Fischel, Jean Louis ^a   Ciccolini, Joseph ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c GSK Oncology   (France)

Author keywords

Breast cancer; Capecitabine; Combination therapy; Lapatinib; Synergism

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863552198     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00945.x     Document Type: Article

References (24)

1. Benzoni E., Rossit L., Cojutti A. et al. Analysis of survival after pancreatic resection for oncological pathologies. Chir. Ital. (2007) 59 17-25.
2. Nelson M.H., Dolder C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother. (2006) 40 261-269.
3. Amundadottir L.T., Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene (1998) 16 737-746.
4. Wood E.R., Truesdale A.T., McDonald O.B. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate and receptor activity in tumor cells. Cancer Res. (2004) 64 6652-6659.
5. Midgley R.S., Kerr D.J., Flaherty K.T. et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann. Oncol. (2007) 18 2025-2029.
6. Siegel-Lakhai W.S., Beijnen J.H., Vervenne W.L. et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin. Cancer Res. (2007) 13 4495-4502.
7. Chu Q.S., Schwartz G., de Bono J. et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J. Clin. Oncol. (2007) 25 3753-3758.
8. Geyer C.E., Forster J., Lindquist D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. (2006) 355 2733-2743.
9. Sonpavde G. Lapatinib plus capecitabine in breast cancer. N. Engl. J. Med. (2007) 356 1471.
10. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. (1984) 22 27-55.
11. Harris B.E., Song R., Soong S.J. et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5 fluorouracil by protracted continuous infusion. Cancer Res. (1990) 50 197-201.
12. Ciccolini J., Cuq P., Evrard A. et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol. Cancer Ther. (2001) 1 133-139.
13. 4 Pteglu assays, in: Rustum Y., McGuire J.J. (Eds), The expanding role of folates and fluoropyrimidines in cancer chemotherapy, Plenum Press, New York, USA, 1988, pp. 97-104.
14. Waterhouse D.N., Madden T.D., Cullis P.R. et al. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. (2005) 391 40-57.
15. Chefrour M., Fischel J.L., Giacometti S. et al. Erlotinib in combination with capecitabine (5′dFUR) in resistant pancreatic cancer cell lines. J. Chemother. (2010) 22 129-133.
16. Carter P., Presta L., Gorman C.M. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. U.S.A. (1992) 89 4285-4289.
17. Brandes A.A., Franceschi E., Tosoni A. et al. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Rev. Anticancer Ther. (2010) 10 179-184.
18. Fendly B.M., Winget M., Hudziak R.M. et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. (1990) 50 1550-1558.
19. Kumar R., Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin. Oncol. (2001) 28 27-32.
20. Cameron D., Casey M., Press M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res. Treat. (2008) 112 533-543.
21. Ciccolini J., Fina F., Bezulier K. et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol. Cancer Ther. (2002) 1 923-927.
22. Tsunoda Y., Suzuki K., Tsunoda A. et al. Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives. Oncol. Rep. (2010) 23 771-777.
23. Nishimura G., Terada I., Kobayashi T. et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol. Rep. (2002) 9 479.
24. Magné N., Fischel J.L., Dubreuil A. et al. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin. Cancer Res. (2003) 9 4735-4742.